Clinical trials: Sleep Disturbances and Insomnia
Sleep Initiation and Maintenance Disorders
Efficacy of Ramelteon in Subjects With Chronic Insomnia
The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.
- Trial name
- NCT00671086
- Testing
- Ramelteon
- Where
- 122 sites in United States
- Volunteers
- 1,213 people
- Sponsor
- Takeda
Insomnia
Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia
The purpose of this study is to determine the long-term effects of Ramelteon, once daily (QD), on endocrine function values.
- Trial name
- NCT00656994
- Testing
- Ramelteon
- Where
- 29 sites in United States
- Volunteers
- 122 people
- Sponsor
- Takeda
Healthy, Sleep Quality
Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep
To demonstrate the influence of a herbal preparation containing hypericum, passionflower, and valerian on sleep structure, improvement of attention, and well-being in comparison to placebo.
- Trial name
- sleep-EEG (NCT00997256)
- Testing
- Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian)), film-coated sugar-pill
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Insomnia Disorder
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.
- Trial name
- NCT06953869
- Testing
- Tasimelteon Oral Suspension
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- Vanda Pharmaceuticals
Chronic Insomnia
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
- Trial name
- DREAM (NCT04325464)
- Testing
- PEAR-003A
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- Pear Therapeutics, Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Sleep Initiation and Maintenance Disorders
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), combined with doxepin in treating subjects with insomnia.
- Trial name
- NCT00755495
- Testing
- Ramelteon and doxepin, Ramelteon, Doxepin
- Volunteers
- 472 people
- Sponsor
- Takeda
Insomnia, Secondary, Sleep Disturbance
Robustness and Usability of the Dreem 3 System for at Home Sleep Monitoring in an Insomnia Population.
There is an unmet medical need for monitoring sleep for multiple nights in a patient's home, without the inconvenience of traveling and staying overnight in a medical center, and without the need for a technician to set up a…
- Conditions
- Insomnia, Secondary, Sleep Disturbance, Sleep, Sleep Initiation and Maintenance Disorders
- Trial name
- NCT05611099
- Testing
- Dreem 3 System vs WatchPAT One, Usability Questionnaire
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dreem
Insomnia
A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment
The purpose of this study is to evaluate the impact of hepatic dysfunction on the pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.
- Trial name
- NCT01257178
- Testing
- LY2624803
- Where
- 4 sites in Germany, Hungary and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Insomnia
Smart Devices-based Longitudinal Assessment of Patterns of Insomnia
The objective of the study is to develop an algorithm to detect insomnia and classify its severity, based on data collected during the use of Withings products and from questionnaires sent to users
- Trial name
- SLEEPI (NCT07430878)
- Testing
- Use of the Withings sleep-related devices, Questionnaires
- Where
- France
- Volunteers
- 17,000 people, healthy volunteers welcome
- Sponsor
- Withings
Insomnia, Hepatic Insufficiency
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
This study will determine whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with moderate and mild hepatic insufficiency are similar to those observed in healthy…
- Trial name
- NCT01043926
- Testing
- Suvorexant
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Insomnia Chronic
An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients with Severe Insomnia
The primary aim of this Real-World Evidence trial is to establish whether short-term (2 weeks) treatment of Chloral Hydrate is effective in patients with severe insomnia which is interfering with normal daily life, and where…
- Conditions
- Insomnia, Insomnia Chronic, Chloral Hydrate
- Trial name
- RESTORE (NCT06053840)
- Testing
- Chloral Hydrate
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Pharmanovia
INSOMNIA
A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia
The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane®, Sanofi-Aventis) in the treatment of insomnia.
- Trial name
- Eszo (NCT01100164)
- Testing
- Eszopiclone, Zopiclone
- Where
- Brazil
- Volunteers
- 263 people
- Sponsor
- Eurofarma Laboratorios S.A.
Insomnia Disorder
Effectiveness of a Digital Health Application for People With Insomnia Disorder (Somnovia)
The trial aims to evaluate the effectiveness of a novel digital health application (somnovia), which was designed to increase sleep quality in persons with insomnia disorder.
- Trial name
- NCT05558865
- Testing
- somnovia
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- Gaia AG
Insomnia, TBI (Traumatic Brain Injury)
Behavioral Treatment of Insomnia in Active-Duty Service Members With Traumatic Brain Injury
The objective of the study is to conduct a randomized controlled trial of Cognitive Behavioral Therapy for Insomnia (CBT-I) in a sample of active-duty sailors with a history of traumatic brain injury (TBI).
- Trial name
- CBTBI (NCT06867666)
- Testing
- In Person CBT-I, CBT-I via COAST
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Noctem, LLC
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097629
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,020 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Disorders
Sleep Satisfaction and Psychomotor Performance of Adults
Primary Objective: To assess sleep satisfaction before and after Zolpidem CR (Ambien CR) administration Secondary Objective: To assess Psychomotor Performance before and after Zolpidem CR (Ambien CR) administration
- Trial name
- MORFEO CR (NCT01097382)
- Testing
- ZOLPIDEM
- Where
- 6 sites in Argentina
- Volunteers
- 30 people
- Sponsor
- Sanofi
Primary Insomnia
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266344
- Testing
- MK0928, gaboxadol / Duration of Treatment 3 Weeks
- Volunteers
- 520 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease (PD)
Observational Study Evaluating Robotic Spinal Mobilization in 16 Parkinson's Disease Participants. The Study Recorded Changes in Mobility, Sit-to-stand Performance, and Pain Scores After a 2-week Intervention With the BackHug Device.
The goal of this completed observational pilot study was to evaluate the immediate and short-term clinical effects of robotic spinal mobilization on motor and non-motor symptoms in community-dwelling adults with Parkinson's…
- Trial name
- NCT07384364
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Pacla Medical Limited
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia
The aim of this trial was to assess the efficacy and safety of Eschscholtzia Californica (EC) in treating patients having psycho-physiologic insomnia in a double-blind randomised placebo controlled trial during a 28-day treatment…
- Trial name
- NCT02183233
- Testing
- Eschscholtzia Californica
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim